JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We developed a methodology for quantitative 3D in silico modeling (q3DISM) of cerebral amyloid-β (Aβ) phagocytosis by mononuclear phagocytes in rodent models of Alzheimer's disease. This method can be generalized for the quantitation of virtually any phagocytic event in vivo.

Abstract

Neuroinflammation is now recognized as a major etiological factor in neurodegenerative disease. Mononuclear phagocytes are innate immune cells responsible for phagocytosis and clearance of debris and detritus. These cells include CNS-resident macrophages known as microglia, and mononuclear phagocytes infiltrating from the periphery. Light microscopy has generally been used to visualize phagocytosis in rodent or human brain specimens. However, qualitative methods have not provided definitive evidence of in vivo phagocytosis. Here, we describe quantitative 3D in silico modeling (q3DISM), a robust method allowing for true 3D quantitation of amyloid-β (Aβ) phagocytosis by mononuclear phagocytes in rodent Alzheimer's Disease (AD) models. The method involves fluorescently visualizing Aβ encapsulated within phagolysosomes in rodent brain sections. Large z-dimensional confocal datasets are then 3D reconstructed for quantitation of Aβ spatially colocalized within the phagolysosome. We demonstrate the successful application of q3DISM to mouse and rat brains, but this methodology can be extended to virtually any phagocytic event in any tissue.

Introduction

Alzheimer's Disease (AD), the most common age-related dementia1, is characterized by cerebral amyloid-β (Aβ) accumulation as "senile" β-amyloid plaques, chronic low-level neuroinflammation, tauopathy, neuronal loss, and cognitive disturbance2. In AD patient brains, neuroinflammation is earmarked by reactive astrocytes and mononuclear phagocytes (referred to as microglia, although their central vs. peripheral origin remains unclear) surrounding Aβ deposits3. As the innate immune sentinels of the CNS, microglia are centrally positioned to clear brain Aβ. However, microglial recruitment to Aβ plaques is accompanied by very little, if any, Aβ phagocytosis4,5. One hypothesis is that microglia are initially neuroprotective by phagocytozing small assemblies of Aβ. However, eventually these cells become neurotoxic as overwhelming Aβ burden and/or age-related functional decline, provokes microglia into a dysfunctional proinflammatory phenotype, contributing to neurotoxicity and cognitive decline6.

Recent Genome-wide Association Studies (GWAS) have identified a cluster of AD risk alleles belonging to core innate immune pathways7 that modulate phagocytosis8-11. Consequently, the immune response to cerebral amyloid deposition has become a major area of interest, both in terms of understanding AD etiology and for developing new therapeutic approaches12-14. Yet, there is a vital need for methodology to evaluate Aβ phagocytosis in vivo. To address this unmet need, we have developed quantitative 3D in silico modeling (q3DISM) to enable true 3D quantitation of cerebral Aβ phagocytosis by mononuclear phagocytes in rodent models of Alzheimer-like disease.

Limited only by the extent to which they recapitulate disease, animal models have proven invaluable for understanding AD pathoetiology and for evaluating experimental therapeutics. Owing to the fact that mutations in the Presenilin (PS) and Amyloid Precursor Protein (APP) genes independently cause autosomal dominant AD, these mutant transgenes have been extensively used to generate transgenic rodent models. Transgenic APP/PS1 mice simultaneously coexpressing "Swedish" mutant human APP (APPswe) and Δ exon 9 mutant human presenilin 1 (PS1ΔE9) present with accelerated cerebral amyloidosis and neuroinflammation15,16. Further, we have generated bi-transgenic rats coinjected with APPswe and PS1ΔE9 constructs (line TgF344-AD, on a Fischer 344 background). Unlike transgenic mouse models of cerebral amyloidosis, TgF344-AD rats develop cerebral amyloid that precedes tauopathy, apoptotic loss of neurons, and behavioral impairment17.

In this report, we describe a protocol for immunostaining microglia, phagolysosomes and Aβ deposits in brain sections from APP/PS1 mice and TgF344-AD rats, and acquisition of large z-dimensional confocal images. We detail in silico generation and analysis of true 3D reconstructions from confocal datasets allowing quantitation of Aβ uptake into microglial phagolysosomes. More broadly, the methodology that we detail here can be used to quantify virtually any form of phagocytosis in vivo.

Protocol

Statement of research ethics: All experiments involving animals detailed herein were approved by the University of Southern California Institutional Animal Care and Use Committee (IACUC) and performed in strict accordance with National Institutes of Health guidelines and recommendations from the Association for Assessment and Accreditation of Laboratory Animal Care International.

1. Rodent Brain Isolation and Preparation for Immunostaining

DAY 1:

  1. Place aged TgF344-AD rats (14-month-old) or APP/PS1 mice (12-month-old) under continuous deep isoflurane anesthesia (4%). Assess the depth of anesthesia by toe pinch and the absence of withdrawal reflex.
  2. Cut through both sides of the rib cage and lift to expose the heart. Insert a 23 G needle into the left ventricle of the heart and make a small incision into the right atrium. Proceed to exsanguination by transcardial perfusion with ice-cold phosphate-buffered saline (PBS) using a peristaltic pump (30 mL for mice; 150 - 200 mL for rats).
  3. Make a caudal midline incision into the skin and move the skin and muscle aside. Cut through the top of the skull along the midline and between the eyes. Remove the bone plates and isolate the whole brain from the skull.
  4. Place the brain into a coronal rodent brain matrix and slice it into quarters. Incubate posterior quarters O/N (16 h) in paraformaldehyde fixative (4% PFA in PBS) at 4 °C. Wash 3x in PBS, and then transfer to 70% ethanol. Caution: PFA is toxic and should be handled under a chemical hood with appropriate personal protection equipment.

DAY 2:

  1. Place brain quarters into embedding cassettes and progressively dehydrate tissue in successively more concentrated 1 h ethanol baths (70%, 80%, 95%, and 100% x3).
  2. Clear ethanol from the tissue with three successive 100% xylene baths (1 h each). Caution: Xylene is toxic and should be handled under a chemical hood with appropriate personal protection equipment.
  3. Embed tissue in paraffin blocks after two molten paraffin wax baths (56 - 58 °C, 90 min each).

DAY 3:

  1. Cut 10 μm-thick sections of paraffin-embedded brains using a microtome. Dip sections into a water bath (50 °C for 1 min) and apply to microscope slides. Leave the slides to dry O/N, ensuring tissue adhesion to the slide.

2. Immunostaining

Note: Different combinations of antibodies can be utilized for the staining procedure described below. Antibody cocktails compatible with brain tissue from rats and mice are listed in Table 1.

DAY 4:

  1. Deparaffinize brain sections using 2x 100% xylene baths (12 min each).
  2. Rehydrate brain sections in successive ethanol baths — 100% for 10 min, 95% for 5 min, 80% for 10 min, and finally 70% for 15 min — followed by 3x PBS washes [5 min at RT, with light agitation]. Meanwhile, heat antigen retrieval solution to 95 - 97 °C on a hot plate with magnetic bar stirring.
  3. Incubate brain sections in antigen retrieval solution at 95 - 97 °C for 30 min. Then, wash 3x in PBS (5 min at RT, with light agitation).
  4. Quickly dry slides using delicate task wipers to avoid tissue drying, and draw a hydrophobic barrier around the tissue area with a hydrophobic barrier pen. Fill the encircled tissue region with blocking buffer [PBS containing 0.3% Triton X-100 and 10% Normal Donkey Serum (NDS)], and incubate at RT for 1 h in a humidified chamber.
  5. Replace blocking buffer with Iba1 primary antibody (diluted in blocking buffer) to label mononuclear phagocytes, and incubate O/N at 4 °C in a humidified chamber. For antibody hosts and working dilutions, see Table 1 and the Table of Materials.

DAY 5:

  1. Rinse primary antibody with 3x PBS baths (5 min at RT with light agitation). Incubate with fluorescent secondary antibody (conjugated with a 594 nm emission fluorophore) for 1 h (in blocking buffer at RT in the dark) followed by 3x PBS baths (5 min at RT with light agitation). At this time, maintain sections in the dark to avoid fluorescent signal bleaching.

DAY 6 - 7:

  1. Repeat steps 2.5 & 2.6 with CD68 (rat brains) or LAMP1 (mouse tissue) antibodies and appropriate secondary antibodies (coupled with a 488 nm emission fluorophore) to label phagolysosomes.

DAY 7 - 8:

  1. Repeat steps 2.5 & 2.6 with OC (rat tissue) or 4G8 (mouse brains) antibodies and appropriate secondary antibodies (coupled to a 647 nm fluorophore) to label Aβ deposits.
    NOTE: Alternatively, 6E10 antibody can be used successfully both on mouse and rat tissue. For appropriate antibody combinations, see the Table of Materials.
  2. Allow sections to completely dry O/N at RT in the dark. Then, cover specimens with a cover slip sealed by fluorescence mounting media containing DAPI.

3. Acquisition of Large Z-stack Confocal Datasets

Note: This protocol requires a fully automated laser scanning confocal microscope equipped with a 60X objective and 405 nm, 488 nm, 594 nm, and 647 nm lasers. All equipment is computer controlled by imaging and laser control software. Prior to beginning the imaging protocol, power on the computer, epifluorescent lamp, microscope, lasers and camera.

DAY 9:

  1. Select the 60X microscope objective. Add immersion oil to the lens, and place the sample onto the microscope stage slide holder. Raise the objective until the oil makes contact with the slide. Adjust the focal plane to locate amyloid plaques in the hippocampus or cerebral cortex using epifluorescent illumination through the oculars.
  2. Acquire confocal images of activated mononuclear phagocytes surrounding amyloid deposits in the hippocampus or cortex of rodents by confocal microscopy (60X magnification, z-stack steps: 0.25 μm < z < 0.40 μm, number of steps 25 < n < 35).

4. q3DISM

Note: In order to yield significant results, we suggest analyzing a minimum of 3 images per animal/region of interest. For each image, the abundance of cells to analyze may vary depending on experimental paradigms. In the representative results shown in this report, we analyzed 3 cells/condition (e.g., mononuclear phagocytes distant from or associated with plaques; see Figures 1C - D and 2C - D).

DAY 10:

  1. Analyze confocal datasets with scientific 3D image processing and analysis software colocalization (coloc) module for spatial proximity of Iba1/CD68 (rat tissue) or Iba1/LAMP1 (mouse tissue) staining in all z-planes simultaneously. Create Iba+/CD68+ or Iba+/LAMP1+ colocalization channels that correspond to phagolysosomes within activated mononuclear phagocytes.
    1. Select TRITC for channel A (corresponding to Iba1 staining coupled with 594 nm fluorophore) and FITC for channel B (corresponding to CD68 or LAMP1 staining coupled with 488 nm fluorophore). On the right-hand side of the software window for 'mode check,' select 'threshold,' and for 'coloc intensities,' select 'source channels'.
    2. Click 'Edit' to select 'coloc color' on the right-hand side of the software window.
    3. For each channel independently, adjust thresholds to include specific staining and exclude background/non-specific signals. Once adjusted, do not change thresholds between images to ensure an unbiased analysis. The colocalized voxels (pixels from all z-stacks) will appear in the color selected in step 4.1.2 in all z-stacks simultaneously.
    4. Click 'build coloc channel'. The colocalization channel created will appear in the display adjustment window.
    5. Click on the coloc channel to open channel statistics. The '% of volume/material A above threshold colocalized' represents the % of Iba1 signal (voxels corresponding to the 594 nm fluorophore) colocalized with LAMP1 or CD68 signal (voxels corresponding to the 488 nm fluorophore). More simply, this is the monocyte volume occupied by phagolysosomes (see Figures 1C and 2C).
      NOTE: '% of volume/material B above threshold colocalized' corresponds to % of LAMP1 or CD68 signal colocalized with Iba1. This should be close to 100%, as phagolysosomes are intracellular structures. Values are based on ratio of signal from all z-stacks above threshold colocalized.
  2. Using the coloc module, analyze the coloc channel created in step 4.1 for spatial proximity with OC (rat tissue) or 4G8 (mouse tissue) Aβ signals. This allows for quantitation of Aβ encapsulated within phagolysosomes.
    1. Select the channel A coloc dataset (corresponding to the Iba1/CD68 or Iba1/LAMP1 coloc channel created in step 4.1) and Cy5 for channel B (corresponding to OC or 4G8 staining coupled with 647 nm fluorophore).
    2. Build a coloc channel as described in steps 4.1.2 to 4.1.5.
    3. Click on the coloc channel to open channel statistics. The '% of volume/material A above threshold colocalized' represents the % of Iba1/LAMP1 or Iba1/CD68 (voxels corresponding to the coloc channel built in step 4.1.5.) colocalized with OC or 4G8 signal (voxels corresponding to the 647 nm fluorophore). This is the phagolysosomal volume occupied by Aβ (see Figures 1D and 2D).
      NOTE: '% of volume/material B above threshold colocalized' corresponds with % of total Aβ signal colocalized with phagolysosomes. This can be used to evaluate the fraction of total Aβ deposits encapsulated within phagolysosomes (not shown in the present representative results).
  3. Use the surpass module to reconstruct the confocal image stacks and generate 3D models of Aβ encapsulated within monocyte phagolysosomes.
    1. In the 'display adjustment' window, select TRITC (to show only Iba1 staining). In the 'volume properties' window, click 'add new surface'.
    2. In step '1/5 algorithm', in 'settings,' select 'surface.' Also, in 'color,' select color type in palette or RGB and adjust transparency (red is set at 60% transparency in Figures 1B and 2B). Check box 'select region of interest'. Click next.
    3. In Step '2/5 region of interest,' draw a window around the cell of interest by adjusting x, y and z coordinates (see white boxes in Figures 1A and 2A). Click next.
    4. In Step '3/5 source channel', select the TRITC source channel. Check the box 'smooth,' and set surface area detail level to 0.4 μm. For 'thresholding,' select absolute intensity. Click next.
    5. In Step '4/5 threshold,' adjust threshold so that the volume created overlaps perfectly with the TRITC channel signal. Click next.
    6. In Step '5/5 classify surfaces,' in section 'filter type,' select objects depending on their size to be included or excluded from the volumes to be created. Click finish, execute all creation steps, and exit the wizard.
    7. Repeat steps 4.3.1 to 4.3.6 to create a 3D surface for the FITC channel (LAMP1+ or CD68+ phagolysosomes).
    8. Repeat steps 4.3.1 to 4.3.6 to create a 3D surface for the Cy5 channel (OC+ or 4G8+ Aβ deposits).

Results

Using the multi-stage methodology for q3DISM detailed above, we are able to quantify Aβ uptake into monocyte phagolysosomes in the brains of APP/PS1 mice (Figure 1) and TgF344-AD rats (Figure 2). Therefore, the q3DISM methodology has enabled analysis of mononuclear phagocytes in mouse and rat models of AD. Interestingly, the volume occupied by CD68+ phagolysosomes is significantly increased in Iba1+ mononuclear phagocytes associ...

Discussion

The protocol that we describe in this report for true 3D quantitation of Aβ phagocytosis in vivo by mononuclear phagocytes relies on specific labeling of cellular and subcellular compartments as well as Aβ deposits. Specifically, we use Iba1 (Ionized-calcium Binding Adaptor molecule 1), a protein that is involved in membrane ruffling and phagocytosis upon cell activation18,19, to stain cerebral mononuclear phagocytes. While Iba1+ cells are generally regarded ...

Disclosures

The authors have nothing to disclose.

Acknowledgements

M-V.G-S. is supported by a BrightFocus Foundation Alzheimer's Disease Research Fellowship Award (A2015309F) and an Alzheimer's Association, California Southland Chapter Young Investigator Award. T.M.W. is supported by an ARCS Foundation and John Douglas French Alzheimer's Foundation Maggie McKnight Russell-JDFAF Memorial Postdoctoral Fellowship. This work was supported by the National Institute on Neurologic Disorders and Stroke (1R01NS076794-01, to T.T.), an Alzheimer's Association Zenith Fellows Award (ZEN-10-174633, to T.T.), and an American Federation of Aging Research/Ellison Medical Foundation Julie Martin Mid-Career Award in Aging Research (M11472, to T.T.). We are grateful for startup funds from the Zilkha Neurogenetic Institute, which helped to make this work possible.  

Materials

NameCompanyCatalog NumberComments
IsofluraneAbbottNDC 0044-5260-05
Dissecting scissorsVWR82027-582
Dissecting scissors Blunt tipVWR82027-588
TweezersVWR94024-408
23 G needleVWRBD305145
peristaltic pump FH10Thermo Scientific72-310-010
PBS 10xBioland ScientificPBS01-02Phosphate-buffered Saline; Working concentration 1x
Adult Mouse Brain Matrix, Coronal slices, Stainless Steel 1 mm Kent ScientificRBMS-200C
Adult Rat Brain Matrix, Coronal slices, Stainless Steel 1 mm Kent ScientificRBMS-305C 
32% Paraformaldehyde aqueous solution (PFA)EMS15714-SCaution: Toxic. Working concentration: 4% in PBS
EthanolVWR89125-188Various concentrations, see protocol
Tissue-Tek Uni-cassettes SakuraVWR25608-774
Embedding and Infiltration ParaffinVWR15147-839
Microtome Leica RM2125Leica Biosystems
Disposable Microtome Blades VWR25608-964
Water bath Leica HI 1210Leica Biosystems
Micro slide Superfrost plusVWR48311-703
XyleneSigma-Aldrich534056-4X4LCaution: Toxic 
Target Retrieval Solution 10xDAKOS1699Working concentration 1x
KimWipesVWR21905-026
Hydrophobic PAP penVWR95025-252
Triton X-100VWR97062-208
Normal Donkey Serum (NDS)Jackson Immuno017-000-121
CoverslipsVWR48393081
Prolong Gold antifade reagent with DAPILife TechnologiesP36935
Glass Slide RackVWR100492-942
Iba1 antibody (polyclonal, rabbit)Wako019-19741 Working concentration 1:200
Iba1 antibody (polyclonal, goat)LifeSpan BioscienceLS-B2645Working concentration 1:200
rat CD68 [KP1] antibody (monoclonal, mouse)Abcamab955Working concentration 1:200
mouse CD68 [FA-11] antibody (monoclonal, rat)Abcamab53444Working concentration 1:200
mouse CD107a (LAMP1) antibody (monoclonal, rat)Affymetrix14-1071Working concentration 1:100
Beta-Amyloid, 17 - 24 (4G8) antibody (monoclonal, mouse)CovanceSIG-39220Working concentration 1:200
Beta-Amyloid, 1 - 16 (6E10) antibody (monoclonal, mouse)CovanceSIG-39320Working concentration 1:200
OC antibody (polyclonal, rabbit)Gifted by D. H. Cribbs and C. G. Glabe (UC Irvine)Working concentration 1:200
Alexa Fluor 488 mouse secondary antibodyInvitrogenA-11001Working concentration 1:1,000
Alexa Fluor 488 rat secondary antibodyInvitrogenA-11006Working concentration 1:1,000
Alexa Fluor 594 rabbit secondary antibodyInvitrogenA-11037Working concentration 1:1,000
Alexa Fluor 594 goat secondary antibodyInvitrogenA-11080Working concentration 1:1,000
Alexa Fluor 647 mouse secondary antibodyInvitrogenA-21235Working concentration 1:1,000
Alexa Fluor 647 rabbit secondary antibodyInvitrogenA-21443Working concentration 1:1,000
Immersion oilNikon 
A1 Confocal microscopeNikon 
NIS Elements Advanced Research softwareNikon 
Imaris:Bitplane software version 7.6Bitplane"coloc" and "supass" modules are used. Alternatively, the open-source freeware ImageJ can be used for colocalization analysis of confocal z-stacks datasets.

References

  1. Brookmeyer, R., et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 7 (1), 61-73 (2011).
  2. Selkoe, D. J. Alzheimer's disease. Cold Spring Harb Perspect Biol. 3 (7), (2011).
  3. Heneka, M. T., Golenbock, D. T., Latz, E. Innate immunity in Alzheimer's disease. Nat Immunol. 16 (3), 229-236 (2015).
  4. Mawuenyega, , et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 330 (6012), 1774 (2010).
  5. Hickman, S. E., Allison, E. K., El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 28 (33), 8354-8360 (2008).
  6. Johnston, H., Boutin, H., Allan, S. M. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans. 39 (4), 886-890 (2011).
  7. Gjoneska, E., et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature. 518 (7539), 365-369 (2015).
  8. Reitz, C., Mayeux, R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 88 (4), 640-651 (2014).
  9. Hazrati, L. -. N., et al. Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol Aging. 33 (12), 2949 (2012).
  10. Griciuc, A., et al. Alzheimer's Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron. , 1-13 (2013).
  11. Li, X., Long, J., He, T., Belshaw, R., Scott, J. Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease. Scientific reports. 5, 12393 (2015).
  12. Weitz, T. M., Town, T. Microglia in Alzheimers Disease: "Its All About Context". Int J Alzheimers Dis. , 314185 (2012).
  13. Guillot-Sestier, M. -. V., Doty, K. R., Town, T. Innate Immunity Fights Alzheimer's Disease. Trends Neurosci. 38 (11), 674-681 (2015).
  14. Guillot-Sestier, M. -. V., Town, T. Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets. 12 (5), 593-607 (2013).
  15. Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., Borchelt, D. R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 17 (6), 157-165 (2001).
  16. Guillot-Sestier, M. -. V., et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 85 (3), 534-548 (2015).
  17. Cohen, R. M., et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci. 33 (15), 6245-6256 (2013).
  18. Imai, Y., Ibata, I., Ito, D., Ohsawa, K., Kohsaka, S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem. Biophys. Res. Commun. 224 (3), 855-862 (1996).
  19. Ohsawa, K., Imai, Y., Sasaki, Y., Kohsaka, S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 88 (4), 844-856 (2004).
  20. Bandyopadhyay, U., Nagy, M., Fenton, W. A., Horwich, A. L. Absence of lipofuscin in motor neurons of SOD1-linked ALS mice. Proc Natl Acad Sci U S A. 111 (30), 11055-11060 (2014).
  21. Holness, C. L., Simmons, D. L. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 81 (6), 1607-1613 (1993).
  22. Connor, T., et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron. 60 (6), 988-1009 (2008).
  23. Cai, D., et al. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A. 103 (6), 1936-1940 (2006).
  24. Marsh, S. E., et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 113 (9), 1316-1325 (2016).
  25. Lefterov, I., et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol. Chem. 285 (47), 36945-36957 (2010).
  26. Blurton-Jones, M., et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 106 (32), 13594-13599 (2009).
  27. Stalder, M., Deller, T., Staufenbiel, M., Jucker, M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 22 (3), 427-434 (2001).
  28. Leinenga, G., Götz, J. Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci Transl Med. 7 (278), 33 (2015).
  29. Liarski, V. M., et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci Transl Med. 6 (230), 46 (2014).
  30. Nichols, L., Pike, V. W., Cai, L., Innis, R. B. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease. Biol Psychiatry. 59 (10), 940-947 (2006).
  31. Skovronsky, D. M., Zhang, B., Kung, M. P., Kung, H. F., Trojanowski, J. Q., Lee, V. M. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 97 (13), 7609-7614 (2000).
  32. Lian, H., Litvinchuk, A., Chiang, A. C. -. A., Aithmitti, N., Jankowsky, J. L., Zheng, H. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci. 36 (2), 577-589 (2016).
  33. Novotny, R., et al. Conversion of Synthetic Aβ to In Vivo Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. J Neurosci. 36 (18), 5084-5093 (2016).
  34. Tartaro, K., et al. Development of a fluorescence-based in vivo phagocytosis assay to measure mononuclear phagocyte system function in the rat. J Immunotoxicol. 12 (3), 239-246 (2015).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Quantitative 3D In Silico ModelingQ3DISMAmyloid beta PhagocytosisAlzheimer s DiseaseRodent ModelsMacrophageImmunostainingConfocal Microscopy

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved